Edison Pharmaceuticals shed its stealth mode and went public with a $545 million-plus collaboration deal with Japan's Dainippon Sumitomo that centers on its lead late-stage drug for rare diseases.
Just days after rounding up $30 million in venture cash, New York-based Intercept Pharmaceuticals is boldly gambling that investors will cough up about $75 million to buy into a late-stage orphan drug for chronic liver disease. The biotech filed for an ambitious IPO, hoping it can avoid the price cuts that most other such development-stage biotech bids have been forced to endure in recent years.
Nitto Denko and Dainippon Sumitomo have started a Phase II trial of a transdermal patch delivering Dainippon Sumitomo's antipsychotic Lonasen (blonanserin), which has been launched in Japan and South Korea.
Boston Biomedical's focus on targeting cancer stem cells has paid off.
Chelsea Therapeutics ($CHTP) has racked up some more positive efficacy data for its lead drug droxidopa, which is now up for review at the FDA. Investigators reported the drug spurred a statistically
While the FDA reviews its application for approval of the experimental drug, Sunovion Pharmaceuticals revealed upbeat data from a major Phase III trial of its ciclesonide nasal aerosol against...
Japan's Dainippon Sumitomo is slapping down $15 million and promising up to $300 million more in milestones in exchange for the rights to Intercept Pharmaceuticals' late-stage liver disease drug in
The FDA has given the green light to Dainippon Sumitomo Pharma's Latuda (lurasidone), an atypical antipsychotic. The drug is designed to work like other atypcals such as Zyprexa, Risperdal or
Last fall, when Dainippon Sumitomo Pharma announced that it had inked a deal to buy Sepracor for $2.6 billion, the Japanese pharma company cited the once-daily epilepsy drug Stedesa as one of the
With the $2.6 billion acquisition of Sepracor by Dainippon Sumitomo drawing to a close soon, the developer's CEO is on his way over to take the helm at Raleigh, NC-based Inspire Pharmaceuticals.